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A B S T R A C T
Purpose: Human photosensitive epilepsy models have been used as proof of principle (POP) trials for
epilepsy. Photosensitive patients are exposed to intermittent photic stimulation and the reduction in
sensitivity to the number of standard visual stimulation frequencies is used as an endpoint. The aim of
this research was to quantify the predictive capabilities of photosensitive POP trials, through a survey of
current literature.
Methods: A literature search was undertaken to identify articles describing photosensitive POP trials.
Minimally efﬁcacious doses (MEDs) in epilepsy were compared to doses in the POP trials that produced
50–100% response (ED50–100). Ratios of these doses were calculated and summarised statistically.
Results: The search identiﬁed ten articles describing a total of 17 anti-epileptic drugs. Of these, data for
both MED and ED50–100 were available for 13 anti-epileptic drugs. The average ratio of MED to ED50–100
was 0.95 (95% CI 0.60–1.30). The difference in MED to ED50–100 ratios between partial epilepsy (0.82) was
not signiﬁcantly different from that of generalised epilepsy (1.08) (p = 0.51).
Conclusion: Photosensitive POP trials are a useful tool to quantitatively predict efﬁcacy in epilepsy, and
can be useful as early and informative indicators in anti-epileptic drug discovery and development.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Proof of principle (POP) trials are used early in drug develop-
ment, typically after phase 1 or early in phase 2, and aim to give an
early read out of potential efﬁcacy. In the area of epilepsy,
biomarkers are not readily available and mechanisms of action
may not be fully elucidated for some classes of drugs. Thus, POP
trials have signiﬁcant potential in anti-epileptic drug (AED)
development by providing early indicators of efﬁcacy, improving
decision-making and potentially reducing the cost of Phase 2/3
failures.
POP trials for epilepsy include inter-ictal discharges, transmag-
netic cranial stimulation or photosensitive epilepsy, of which the
ﬁrst two have been associated with variable responses or providingAbbreviations: POP, proof of principle; MED, minimally efﬁcacious dose; ED50–100,
doses at which 50–100% of patients had positive response; AED, anti-epileptic drug.
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be a reliable early indicator of pharmacodynamic activity for a
number of novel AEDs.2–5 In these trials, photosensitive epileptic
patients are exposed to intermittent photic stimulation and the
provocation of paroxysmal discharges is monitored. The outcome
measured is the number of standard visual stimulation frequencies
to which the patient is sensitive, and response can generally be
classiﬁed as complete abolishment of sensitivity, partial or none.
Since photosensitive POP trials have already been shown
qualitatively to be an early indicator of pharmacodynamic activity,
the aim of this research was to take a step further to quantify the
predictive capabilities of photosensitive POP trials, in order to
better characterise the utility of such trials in epilepsy drug
development. This was done through a survey of current literature
reporting results on photosensitive POP trials.
2. Materials and methods
A literature search was undertaken in PubMed (http://
www.ncbi.nlm.nih.gov/pubmed/) using four different combina-
tions of keywords. The ﬁrst search used ‘‘photosensitive’’ andserved.
Table 1
Literature survey search strategy and results.
Search number Keywords No. of e-articles ahead of print Filters used No. of results retrieved No. of articles included
1 Photosensitive, epilepsy 12 Clinical trial 19 5
2 Photosensitivity, epilepsy 20 Clinical trial 38 2a
3 Photosensitive, epilepsy, model 0 Human 49 3a
4 Photosensitivity, epilepsy, model 0 Human 21 0a
a Duplicate articles from previous searches were not included.
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with ‘‘photosensitivity’’. This was then repeated for the third and
fourth searches by adding the term ‘‘model’’. Search results were
sorted by recently added articles and all e-publications ahead of
print were separately identiﬁed prior to the addition of ﬁlters of
‘‘clinical trial’’ and/or ‘‘humans’’ to the results. Articles describing
photosensitive POP trials using a single dose of AED were included,
whilst articles describing clinical trials for non-drug treatment or
chronic treatment of photosensitive epilepsy with AEDs were
excluded.
Minimally efﬁcacious doses (MEDs) for treatment of epilepsy
(partial, generalised or both) for approved AEDs described in the
POP trials were obtained from the respective drug labels. For non-
approved AEDs, a search was conducted in PubMed (http://
www.ncbi.nlm.nih.gov/pubmed/) using the drug name as keyword
and limited to clinical trials. MEDs were determined from double-
blind, placebo controlled trials in partial or generalised epilepsy
where signiﬁcance from placebo was observed. Where more than
one trial was available for a particular drug, the average across the
lowest efﬁcacious doses in each trial was obtained. In the POP
trials, efﬁcacious doses were deﬁned as dose levels in which 50–
100% of patients had a positive response (ED50–100), where a
response was considered to be either a complete abolishment or a
signiﬁcant partial decrease in sensitivity to standard visual
frequencies. No attempt was made to distinguish between these
two types of positive responses since small numbers of patients
(majority of trials had 4–6 patients per dose level, range 1–14)
were typically tested at each dose level.
For each AED, the ratio of MED to ED50–100 was calculated
when both values were available, since efﬁcacy data was notTable 2
Anti-epileptic drugs investigated in photosensitive POP trials and the comparisons to m
AED Doses investigated in
POP trial (mg)
ED50–100 (mg) MED (type of 
indicated)a
Diazepam 5 5 2 mg (adjunct
disorders)
Sodium valproate 600, 900 600 600 mg (partia
Mephenytoin 400 400 200 mg (gener
Progabide 1200–1800, 2700 1200–1800 1800 mgc (par
Ethosuximide 400 400 500 mg (gener
Primidone 500 500 750 mg (gener
Lamotrigine 120, 240 240 225 mg (partia
Naﬁmidone 200, 400 400 600 mgd (part
Carbamazepine 400 400 800 mg (partia
Loreclezole 100–110, 150 100 12.5 mge (part
Levetiracetam 250, 500, 750, 1000 500–1000 1000 mg (part
Carisbamate 500, 750, 1000 500–1000 350 mgf (parti
Brivaracetam 10, 20, 40, 80 10 5 mgg (partial
a Minimally efﬁcacious doses in epilepsy obtained from professional monographs on
b If ED50–100 is presented as a range of values, the average value is used for ratio ca
c Average calculated from Martinez et al.,12 de Pasquet et al.13 and Loiseau et al.14
d Obtained from Treiman et al.15
e Obtained from Rentmeester et al.16
f Average calculated from Faught et al.17 and Sperling et al.18
g Obtained from French et al.19available for all drugs used in photosensitive POP trials. The
ratios were described by summary statistics. No weighting
factor was included for study size and/or quality since the
conduct of most of these trials were similar using small numbers
of patients.
3. Results
In total, ten articles were identiﬁed that ﬁt the inclusion
criteria.2–11 The results of the literature search are described in
Table 1. Of the ten, eight described positive results only, one
described an unexpected increase in photosensitive epilepsy when
patients were given Org 6370,6 and another described mixed
results with two marketed AEDS (carbamazepine and levetirace-
tam).10 These ten articles described the use of a total of 17 drugs in
photosensitive epilepsy POP trials, however efﬁcacy data (MED)
was only found for 13 drugs, since some drugs had not undergone
phase 2/3 trials or the trial results had not been reported at the
time of conducting the search.
Of the 13 AEDs, six were indicated in partial seizures, three in
generalised seizures and three in both types. The doses investigat-
ed in the POP trials were either close to, or encompassed the MED
for epilepsy. The results show that across the AEDs, the average
ratio of MED to ED50–100 was 0.95 (95% CI 0.60–1.30) with all ratios
contained within 2-fold. The difference in MED to ED50–100 ratios
between partial epilepsy (0.82, 95% CI 0.46–1.18) was not
signiﬁcantly different from that of generalised epilepsy (1.08,
95% CI 0.60–1.56) (p = 0.51). The ratios of MED to ED50–100 for each
AED are reported in Table 2.inimally efﬁcacious doses in epilepsy.
seizure Ratio MED:ED50–100
b Reference
 in convulsive 0.4 Binnie et al.5
l) 1
alised) 0.5
tial + generalised) 1.2
alised) 1.3
alised) 1.5
l + generalised) 0.9
ial) 1.5
l + generalised) 2
ial) 0.13 Overweg et al.8
ial) 1.3 Kastelijn-Nolst Trenite´ at al.2
and French et al.10
al) 0.4 Kastelijn-Nolst Trenite´ et al.3
) 0.5 Kastelijn-Nolst Trenite´ et al.4
 www.drugs.com unless otherwise stated.
lculations.
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This literature survey investigated the utility of photosensi-
tive POP trials for quantitatively predicting efﬁcacy in partial or
generalised epilepsy. This was achieved by comparing the
efﬁcacious doses in photosensitive POP trials versus the
efﬁcacious doses of marketed AEDs or those reported in late-
stage clinical trials for AEDs currently under investigation. The
results showed that single dose photosensitive POP trials can be
a reliable quantitative indicator of efﬁcacy in epilepsy, with the
average ratio of epilepsy MEDs to doses associated with 50–
100% responses in the photosensitive POP trials of 0.95. Where
individual ratios were less than 1, the ED50–100 was captured in
the usual maintenance dose range for marketed AEDs. This is a
particularly encouraging result for drug development of AEDs,
since photosensitive POP trials use only a single dose and thus
can be conducted immediately after a single dose ascending
study. The probability of technical success can be increased
early in drug development, with the results from the POP trial
not only indicating potential efﬁcacy in epilepsy, but also
providing information for dose selection in phase 2 and phase 3
epilepsy trials. It may also be used as a tool to screen drugs for
new indications in epilepsy, as in the case of pitolisant, a
histamine-3 receptor (H3R) antagonist, where drug develop-
ment efforts have been initially focused on narcolepsy,
Parkinson’s disease and obstructive sleep apnea.7
Of the total of 17 drugs identiﬁed in the literature survey, only
two drugs were reported to have failed in the photosensitive POP
trials. Carbamazepine showed positive results in an earlier study,5
but the ﬁndings could not be replicated in a recent study at the
same dose.10 The authors postulated that drug concentration levels
for carbamazepine were not available from the earlier trial and
may have explained the differences between the two studies. The
other reported drug that failed in the photosensitive POP trials was
Org 6370, despite having shown efﬁcacy in animal epilepsy
models.6 Information on AED efﬁcacy in humans for this drug was
not available, therefore it was not possible to assess if this was a
true or false negative. One of the major caveats of this analysis is
that only true positive cases (and a mixed case with carbamaze-
pine) have been shown. The omission of false positive or false
negative cases does not indicate the lack of such cases, but rather
these are less likely to be reported.2 Therefore, it is important to
acknowledge that a positive photosensitive POP trial will not
necessarily guarantee future success in an epilepsy efﬁcacy trial
and vice versa. Other caveats that need to be taken into
consideration for interpretation of the results of this literature
survey include the small numbers of subjects (usually N = 4–6 per
cohort) who are often co-medicated but stable on other AEDs.
Although blood samples were taken to ensure the drug levels of the
co-medications were not altered on administration of the
investigative drug, a pharmacodynamic interaction (e.g. syner-
gism) may still be present. Some AEDs identiﬁed in this literature
survey may no longer be prescribed or frequently used due to
efﬁcacy or toxicity proﬁles which have since emerged. This is to be
expected since these tend to be older drugs with a higher
likelihood of being discarded in favour of newer ones with better
safety-efﬁcacy balance. The aim of the current literature survey
was to use photosensitive trials POP trials to predict efﬁcacy rather
than safety, hence it was deemed advantageous to look across a
wide range of drugs that have shown some degree of efﬁcacy in the
treatment of epilepsy, especially since the disease area may still
not be well understood.
Approximately 70% of photosensitive patients with a history
of epilepsy have generalised epilepsy versus 30% with partial
epilepsy.8 Thus, one could postulate that results from photo-
sensitive POP trials may be more indicative of efﬁcacy ingeneralised rather than partial epilepsy. Whilst the biology of
the ability of the photosensitivity model to predict efﬁcacy in
non-photosensitive epilepsy is not well understood and may be
overestimated because of a positive publication bias, it would
appear that a positive effect in the POP trials strongly suggests
efﬁcacy in other epilepsy syndromes. Of the AEDs presented in
this paper, nine are indicated in partial epilepsy and six are
indicated for generalised epilepsy but there was no signiﬁcant
difference in MED:ED50–100 ratios between drugs used for
treatment of partial and generalised epilepsy. This would
suggest that results of photosensitive POP trials are equally
applicable in prediction of drug efﬁcacy in both partial and
generalised seizures. Clinicians appreciate that many non-photic
epilepsies have varied triggers, such as stress, lack of sleep or
speciﬁc sensory stimuli, however the issue with these triggers is
their lack of reproducibility. The photosensitivity model’s
success is lies in its reproducibility to trigger rather than the
speciﬁcity of the epileptic circuitry that exists for these
particular patients or even some of the similar photosensitive
animal models. We would hypothesize that drugs that are highly
speciﬁc, for a type of circuit or type of propagation, which exists
beyond a photosensitive model, could generate a false negative
signal.
In conclusion, photosensitive POP trials are a useful tool to
quantitatively predict efﬁcacy in epilepsy. Doses corresponding to
50–100% response in these POP trials were found to be within 2-
fold to the minimally efﬁcacious doses used in partial or general
epilepsy. Thus, single dose photosensitive POP trials can be useful
as early and informative indicators in AED discovery and
development, particularly in aiding dose selection in phase 2
and 3 epilepsy trials.
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